What To Know
- RMED) (Ra Medical), a medical device and technology company focused on cardiac electrophysiology, announces that four abstracts with clinical data supporting its VIVO technology have been accepted for presentation at the European Heart Rhythm Association Congress (EHRA 2023) being held April 16-18, 2023 in Barcelona.
- “It is highly gratifying to present clinical data to the many electrophysiology thought leaders at the largest European meeting solely focused on arrhythmia management and treatment,” said David Jenkins, Ra Medical Systems Executive Chairman.
Ra Medical Systems, Inc. (NYSE American: RMED) (Ra Medical), a medical device and technology company focused on cardiac electrophysiology, announces that four abstracts with clinical data supporting its VIVO technology have been accepted for presentation at the European Heart Rhythm Association Congress (EHRA 2023) being held April 16-18, 2023 in Barcelona. VIVO, developed by Ra Medical’s wholly owned subsidiary Catheter Precision, is a proprietary AI system used to non-invasively identify the origin of ventricular arrhythmias prior to an ablation procedure.
“It is highly gratifying to present clinical data to the many electrophysiology thought leaders at the largest European meeting solely focused on arrhythmia management and treatment,” said David Jenkins, Ra Medical Systems Executive Chairman. “All four abstracts with VIVO clinical data submitted by leading physicians to the Congress were accepted for presentation following an extensive peer-review process. To have one-hundred percent acceptance of submitted abstracts is rare and I believe indicative of the positive impact VIVO is having on ventricular ablation procedures. We view this recognition as a major milestone in gaining clinical acceptance by both EP thought leaders and the larger medical community.”
About EHRA
EHRA is a branch of the European Society of Cardiology (ESC). The European Heart Rhythm Association (EHRA) is the leading network of European Cardiac Rhythm Management with more than 4,100 members around the globe, including physicians, arrhythmia experts, electrophysiologists, nurses and allied professionals. The EHRA Congress brings together industry professionals to learn, discover and educate them on new and innovative technologies that impact arrhythmia treatment.
About VIVO
Catheter Precision’s VIVO™ (View Into Ventricular Onset) is a non-invasive 3D imaging system that enables physicians to identify the origin of arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.